BioSyent (CVE:RX) Stock Price Crosses Above Fifty Day Moving Average – What’s Next?

Shares of BioSyent Inc. (CVE:RX) passed above its 50-day moving average during trading on Thursday . The stock has a 50-day moving average of C$11.35 and traded as high as C$11.43. BioSyent shares last traded at C$11.43, with a volume of 100 shares trading hands.

BioSyent Price Performance

The stock’s fifty day moving average is C$11.36 and its 200-day moving average is C$10.80. The stock has a market capitalization of C$129.46 million, a PE ratio of 18.62 and a beta of 0.93. The company has a debt-to-equity ratio of 3.19, a current ratio of 6.13 and a quick ratio of 6.91.

Insider Buying and Selling

In other news, insider FAX Capital Corp. sold 230,800 shares of the stock in a transaction dated Friday, November 22nd. The shares were sold at an average price of C$11.12, for a total value of C$2,566,496.00. Also, Senior Officer Robert Joseph March sold 4,775 shares of the stock in a transaction dated Thursday, December 12th. The shares were sold at an average price of C$11.65, for a total transaction of C$55,628.75. Over the last three months, insiders have sold 349,144 shares of company stock valued at $3,903,370. Corporate insiders own 33.65% of the company’s stock.

BioSyent Company Profile

BioSyent Inc, together with its subsidiaries, acquires or licenses, develops, and sells pharmaceutical and other healthcare products in Canada and internationally. Its products include FeraMAX Pd Therapeutic 150 for the treatment of iron deficiency anemia; FeraMAX Pd Maintenance 45, a chewable supplement for the prevention of iron deficiency anemia; and FeraMAX Pd Powder 15, a powder form product used for preventing iron deficiency and iron deficiency anemia.